Pharmacogenetics
Driving personalized care through genome diversity
Diversity drives treatments,
precision makes it yours
Pharmacogenetics is transforming the way we approach treatments.
By analyzing each patient’s genetic profile, healthcare professionals can predict drug response, minimize adverse effects, and tailor therapies with unprecedented precision. This patient-centered approach not only enhances treatment safety and efficacy but also improves quality of life, making medicine truly personal.
Accessibility
Making pharmacogenetic testing affordable, fast, and easy to integrate into everyday care—so precision medicine reaches every patient, everywhere.
Comprehensiveness
Offering broad genetic coverage focused on clinically relevant variants is crucial to truly support access to precision medicine.
Clinical Impact
Providing advanced bioinformatic tools to support clinicians in personalizing treatment choices and translating genetic data into actionable insights aligned with national and international guidelines.
Discover our complete solutions for pharmacogenetics profiling
EasyPGX®
The dry qPCR revolution for pharmacogenetics genoptyping
EasyPGX is the easy-to-use RT-PCR IVD testing solution made to speed up pharmacogenetic genotyping, supporting the democratization of precision medicine.
Ready to use
Fast
Regulatory compliant
Comprehensive DPYD and UGT1A1 Genotyping — Simplified with EasyPGX®
EasyPGX® combines fast turnaround, intuitive workflow, and complete variant detection consistent with international pharmacogenetic recommendations, supporting safer and more effective patient care.
DPYD
- 3-8% of people carry DPYD variants, affecting fluoropyrimidine metabolism.
- Up to 10X higher risk of severe toxicity associated with fluoropyrimidine treatment, in patients with DPYD mutations
- 1% of fatality rate associated with fluoropyrimidine toxicity.
- 90% of severe toxicity can be prevented by preemptive DPYD genotyping.
DPYD gene mutations recommended by the main international guidelines and included in EasyPGX® Ready DPYD kit
- DPYD (IVS10C>G, HapB3)
- DPYD*13 (c.1679T>G)
- DPYD*2A (IVS14+1G>A, c.1905+1G>A)
- DPYD c.2846A>T
- DPYD*6 c.2194G>A
UGT1A1
- >20% of individuals carry UGT1A1 variants affecting irinotecan metabolism.
- 30% of patients experience severe toxicity associated with irinotecan treatment
- Up to 4X higher toxicity risk in homozygous *28/*6 UGT1A1 variant carriers compared to WT, associated with irinotecan treatment.
- 70% of toxicities preventable with preemptive UGT1A1 genotyping.
UGT1A1 gene mutations recommended by the main international guidelines and included in EasyPGX Ready UGT1A1 kit:
- UGT1A1*28
- UGT1A1*6
EasyPGX® workflow
Enhance your diagnostic routine to accelerate personalized medicine
Nucleic Acid extraction
PCR setup
Add extracted samples to ready-to-use 8-well strip
<5 min
TURNAROUND TIME
<5 min
HANDS-ON
PCR run
Load the strip onto the thermal-cycler and start the run
90 min
TURNAROUND TIME
<1 min
HANDS-ON
Data analysis
Import raw data into the EasyPGX® Analysis Software
<1 min
TURNAROUND TIME
<1 min
HANDS-ON
EasyPGX® Analysis Software
Streamline your data analysis process
- No cloud or external data sharing required
- Automated variant calling and raw data checking combined in a single software solution.
- data export and reporting available in various common file formats.
Myriapod® NGS PGX Sign Panel
Advanced Pharmacogenetics Signature for Personalized Therapy
The Myriapod® NGS PGX Sign Panel is a next-generation sequencing (NGS) solution designed to advance personalized medicine by identifying genomic variants in genes involved in the absorption, distribution, metabolism, and excretion (ADME) of drugs.
Comprehensive
Easy & Fast
Regulatory
The genetic passport to
safer, smarter treatments
Pharmacogenetic profiling is essential to anticipate drug response and prevent adverse reactions. The Myriapod® NGS PGX Sign Panel provides comprehensive germline analysis to support therapeutic decisions across multiple specialties—from oncology to cardiology, psychiatry, neurology, infectious diseases and beyond—supporting truly personalized care before treatment begins.
20 genes- extensive gene coverage
> 1000 SNV analysed
>95 associated drugs
Based on CPIC & DPWG guidelines
Ready to use format
Integrated data management system
Myriapod® NGS workflow
NGS made Easy.
Results made Faster
Library prep
Indexing
Pooling and
quantification
Sequencing
Data
analysis
<3 days
TURNAROUND TIME
Myriapod® NGS Data Analysis
On-Premise Bioinformatics for Clinical Genomics
The Myriapod® NGS Data Analysis suite is a robust, on-premise bioinformatics solution combining a high-performance workstation with proprietary software for streamlined NGS data processing, even in a non-bioinformatic expert environment.
- Smart Variant Analysis: SNVs, InDels, CNV automatically identified – no bioinformatics expertise needed.
- Total Data Protection: 100% local processing. No cloud. No external servers. No compromises.
- QC You Can Trust: Automatic run and sample validation, every time.
- Built-In Intelligence: Variants are classified instantly using trusted genomic databases
- PharmCAT database included: to support clinical interpretation of detected variants.